← All trials
NCT04974138
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 22, 2021
- Primary completion
- Jul 31, 2026
- Completion date
- Jul 31, 2026
- First posted
- Jul 23, 2021
- Last posted
- Jul 23, 2021
- Enrollment
- 25000
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shenzhen Ausa Pharmed Co.,LtdLead sponsor
- Peking UniversityOverall official - principal investigator
- Peking UniversityCollaborator
- Shanxi Medical UniversityCollaborator
- Harbin Medical UniversityCollaborator
- Nanchang UniversityCollaborator
- The First People's Hospital of LianyungangCollaborator
- Shenzhen CCHRPP Biomedical InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.